All 13 Biotech & Life Sciences posts we have indexed from venture capital blogs and newsletters, plus the highest-scoring pieces of the past year and the people who write about it most.
AI-driven molecular design is closing the loop between computational predictions and wet lab validation, but the bottleneck isn't automation of equipment—it's reliably interpreting experimental results to guide the next design iteration.
Clinical AI is shifting from administrative tasks to diagnosis and treatment decisions, driven by consumer demand and physician shortages. Success requires navigating regulatory complexity, reimbursement uncertainty, and the autonomy curve—not just raw model performance.
Scientists' lab protocols contain thousands of undocumented decisions that create unexplained variation in results, hindering drug development and manufacturing scale-up. Transfyr is building observability infrastructure to capture what actually happens in experiments, not just what protocols say should happen.
AI is poised to accelerate molecular discovery, but the bottleneck is synthesis: generating the experimental data needed to train models. Rebuilding US chemical synthesis capacity—through automation, closed-loop labs, and agentic integration—is both a massive commercial opportunity and a strategic necessity to avoid dependence on China.
GLP-1 drugs (semaglutide, tirzepatide) generated $71B in 2025—outearning OpenAI and Anthropic combined—while reaching under 2% of eligible patients globally. As new trials reveal benefits beyond obesity (addiction, kidney disease, cardiovascular), the addressable market and revenue potential expand dramatically.
AI's promise to cure disease via superintelligence rests on false assumptions: we lack mechanistic understanding of most diseases, and AI excels only where feedback loops are fast—not in drug discovery, where clinical validation takes years and costs millions.
As AI models grow more capable at proposing scientific experiments, access to high-throughput laboratories becomes a critical bottleneck for training and validation. Companies like Periodic Labs and C5R are building infrastructure to connect AI agents directly to wet labs, creating tight feedback loops between model development and experimental data.
AI has collapsed the economics of discovery in hard sciences, transforming venture's investment landscape from software-first to deep tech-first, accelerated by founder proof points and geopolitical demand for sovereignty.
Not Boring (4) · Vickram Pradhan (3) · Radical VC (3) · Annelies Gamble (3) · Making Connections by Jax (1) · Teddy Blank (1) · 7wire Ventures (1) · Chamath Palihapitiya (1) · Nkechi Iregbulem (1) · Brian Sugar (1)
Suggest a blog or newsletter for the SandHill index. We track the RSS feed and feature the best pieces in the weekly digest.
The latest theses & analyses from 800+ venture investors, curated into one email. Join 5,000+ investors, founders and LPs.